Limited advances in therapy of glioblastoma trigger re-consideration of research policy
- PMID: 26052048
- DOI: 10.1016/j.critrevonc.2015.05.013
Limited advances in therapy of glioblastoma trigger re-consideration of research policy
Abstract
Glioblastoma (GB - WHO grade IV) is the most frequent and lethal primary brain tumour with median overall survival of 7-15 months after diagnosis. As in other cancer research areas, an overwhelming amount of pre-clinical research acquisitions in the GB field have not been translated to patients' benefit, potentially due to inappropriate treatment schedules and/or trial designs in the clinical setting. The recent failure of promising anti-VEGF bevacizumab to improve GB patients' overall survival recapitulates this sense of frustration. The following measures are proposed.
Keywords: Bevacizumab; Bibliometrics; Glioma; Treatment protocol; Treatment quality.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
